M. A. Woodhead (Manchester, United Kingdom), W. Boersma (Oudorp, The Netherlands)
Residual pulmonary abnormalities after L. pneumophila pneumonia: risk factors, radiological findings and functional disturbances R. E. Jonkers, K. D. Lettinga, O. M. van Delden, C. M. Roos, P. Speelman, H. M. Jansen (Amsterdam, The Netherlands)
| |
Factors associated with unknown aetiology in patients with community-acquired pneumonia T. Bauer, S. Ewig, M. A. Marcos, J. Angrill, A. Rano, A. de Roux, J. Mensa, J. A. Martinez, J. Puig de la Bellacasa, A. Torres (Bochum, Bonn, Germany; Barcelona, Spain)
| |
Community-acquired pneumonia (CAP) in alcoholic patients (AL): differences in aetiology and severity A. de Roux, E. Garcia, M. A. Marcos, R. Estruch, P. Mensa, A. Torres (Barcelona, Spain)
| |
Validation of indices and predictive rules of severity for community-acquired pneumonia S. Ewig, A. de Roux, J. Mensa, M. A. Marcos, M. Niederman, A. Torres (Bonn, Germany; Barcelona, Spain; New York, United States Of America)
| |
Discharge delay in patients with community-acquired pneumonia (CAP) treated with a pneumonia critical pathway J. J. Moeller, M. Ma, P. Hernandez, T. Marrie, W. Patrick (Halifax, Edmonton, Canada)
| |
Earlier discharge of patients treated with moxifloxacin IV/PO monotherapy (MXF) versus amoxicillin/clavulanate (AMC) ±] clarithromycin (CLA) for community-acquired pneumonia (CAP) results in cost savings to the German and French healthcare M. Drummond, D. Becker, M. Hux, J. Chancellor, I. Duprat-Lomon, P. P. Sagnier (Heslington, Amersham, Stoke Court/Stoke Poges, United Kingdom; Burlington, Canada; Puteaux, France)
| |
Telithromycin is effective in the treatment of high-risk patients with community-acquired pneumonia L. Hagberg, S. Jenkins, R. Nusrat (Goteborg, Sweden; Bridgewater, United States Of America)
| |
Telithromycin is as effective as comparator antibacterials in the treatment of lower respiratory tract infections M. Zervos, S. Jenkins, R. Nusrat (Royal Oak, Bridgewater, United States Of America)
| |